Breakthrough Pill Extends Pancreatic Cancer Survival

A breakthrough pill called daraxonrasib is giving advanced pancreatic cancer patients a fighting chance—doubling survival time and improving quality of life in a landmark study. Targeting a previously unreachable mutated protein, this drug outperformed chemotherapy, with patients living 13.2 months versus 6.7 months. Doctors were moved by the results, and regulators are fast-tracking approval. It could even open doors for earlier use and surgery eligibility—offering hope where there was once little.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an a...